Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17196712 | 0.86 | CYP3A4 (0.44) | CYP3A4AR | |
| SCHEMBL4538729 | 0.83 | AR (0.43) | AR | |
| SCHEMBL2957496 | 0.79 | AR (0.34) | CYP3A4AR | |
| SCHEMBL2956221 | 0.79 | CYP3A4 (0.48) | CYP3A4AR | |
| SCHEMBL23213309 | 0.78 | CYP3A4 (0.55) | CYP3A4 | |
| SCHEMBL11475560 | 0.78 | CYP3A4 (0.55) | CYP3A4 | |
| SCHEMBL29796103 | 0.78 | CYP3A4 (0.55) | CYP3A4 | |
| SCHEMBL17196738 | 0.77 | CYP3A4 (0.33) | CYP3A4 | |
| SCHEMBL1968727 | 0.76 | AR (0.50) | CYP3A4AR | |
| SCHEMBL45966 | 0.75 | CYP3A4 (0.68) | CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150299120-A1 | Spirohydantoin compounds and their use as selective androgen receptor modulators | AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) | 2015-10-22 | — | — | US | disclosed |
| US-20150299120-A1 | Spirohydantoin compounds and their use as selective androgen receptor modulators | AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) | 2015-10-22 | — | — | US | disclosed |
| US-20150299120-A1 | Spirohydantoin compounds and their use as selective androgen receptor modulators | AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) | 2015-10-22 | — | — | US | disclosed |
| EP-2819999-A1 | SPIROHYDANTOIN COMPOUNDS AND THEIR USE AS SELECTIVE ANDROGEN RECEPTOR MODULATORS | Novartis AG (CH) | 2015-01-07 | — | — | EP | disclosed |
| WO-2013128421-A1 | SPIROHYDANTOIN COMPOUNDS AND THEIR USE AS SELECTIVE ANDROGEN RECEPTOR MODULATORS | NOVARTIS AG (CH) | 2013-09-06 | — | — | WO | disclosed |
| WO-2013128421-A1 | SPIROHYDANTOIN COMPOUNDS AND THEIR USE AS SELECTIVE ANDROGEN RECEPTOR MODULATORS | NOVARTIS AG (CH) | 2013-09-06 | — | — | WO | disclosed |
| US-8168667-B2 | Imidazolidine derivatives, uses therefor, preparation thereof and compositions comprising such | GALAPAGOS NV (BE) | 2012-05-01 | — | — | US | disclosed |
| EP-2026799-B1 | IMIDAZOLIDINE DERIVATIVES, USES THEREFOR, PREPARATION THEREOF AND COMPOSITIONS COMPRISING SUCH | GALAPAGOS SAS (FR) | 2011-06-22 | — | — | EP | disclosed |
| US-20100210699-A1 | IMIDAZOLIDINE DERIVATIVES, USES THEREFOR, PREPARATION THEREOF AND COMPOSITIONS COMPRISING SUCH | DART THERAPUTICS, LLC. | 2010-08-19 | — | — | US | disclosed |
| US-7772267-B2 | or other nuclear hormone receptors inhibitors; 4-(7-Hydroxy-1,3-dioxo-tetrahydropyrrolo[1,2-c]imidazol-2-yl)-5,6,7,8-tetrahydronaphthalene-1-carbonitrile; age-related diseases: sarcopenia, muscular atrophy, lipodistrophy, long-term critical illness, chronic fatigue syndrome, bone fracture repair | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-08-10 | — | — | US | disclosed |
| EP-1722793-A1 | BICYCLIC MODULATORS OF ANDROGEN RECEPTOR FUNCTION | Brystol-Myers Squibb Company (US) | 2006-11-22 | — | — | EP | disclosed |
| EP-1506178-A4 | BICYCLIC MODULATORS OF ANDROGEN RECEPTOR FUNCTION | BRISTOL MYERS SQUIBB CO (US) | 2006-05-24 | — | — | EP | disclosed |
| WO-2005087232-A1 | BICYCLIC MODULATORS OF ANDROGEN RECEPTOR FUNCTION | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-09-22 | — | — | WO | disclosed |
| US-20050197359-A1 | Bicyclic modulators of androgen receptor function | BRISTOL-MYERS SQUIBB COMPANY | 2005-09-08 | — | — | US | disclosed |
| US-20050153968-A1 | Monocyclic N-aryl hydantoin modulators of androgen receptor function | BRISTOL-MYERS SQUIBB COMPANY | 2005-07-14 | — | — | US | disclosed |
| WO-2005049580-A1 | MONOCYCLIC N-ARYL HYDANTOIN MODULATORS OF ANDROGEN RECEPTOR FUNCTION | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-06-02 | — | — | WO | disclosed |
| EP-1506178-A2 | BICYCLIC MODULATORS OF ANDROGEN RECEPTOR FUNCTION | Bristol-Myers Squibb Company (US) | 2005-02-16 | — | — | EP | disclosed |
| US-20040181064-A1 | Bicyclic modulators of androgen receptor function | BRISTOL-MYERS SQUIBB COMPANY | 2004-09-16 | — | — | US | disclosed |
| US-20040019063-A1 | Bicyclic modulators of androgen receptor function | BRISTOL-MYERS SQUIBB COMPANY | 2004-01-29 | — | — | US | disclosed |
| WO-2003096980-A2 | BICYCLIC MODULATORS OF ANDROGEN RECEPTOR FUNCTION | BRISTOL-MYERS SQUIBB COMPANY (US) | 2003-11-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040019063-A1 | Bicyclic modulators of androgen receptor function | AR, NR5A1, ESRRA | CYP3A4 350/4885AR 1/4885 |
| US-20050197359-A1 | Bicyclic modulators of androgen receptor function | AR, ESRRA, NR5A1 | CYP3A4 547/4885AR 1/4885 |
| US-20040181064-A1 | Bicyclic modulators of androgen receptor function | AR, NR5A1, ESRRA | CYP3A4 341/4885AR 1/4885 |
| US-20100210699-A1 | IMIDAZOLIDINE DERIVATIVES, USES THEREFOR, PREPARATION THEREOF AND COMPOSITIONS COMPRISING SUCH | NR5A1, AR, HSD17B7 | CYP3A4 84/4885AR 2/4885 |
| US-20150299120-A1 | Spirohydantoin compounds and their use as selective androgen receptor modulators | NR5A1, AR, SRD5A1 | CYP3A4 345/4885AR 2/4885 |
| US-20050153968-A1 | Monocyclic N-aryl hydantoin modulators of androgen receptor function | AR, NR5A1, CYP19A1 | CYP3A4 791/4885AR 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.